Verge Genomics
A clinical-stage biotechnology company using a proprietary human-centric platform to discover and develop novel therapeutics for neurodegenerative diseases.
What is Verge Genomics?
Verge Genomics specializes in accelerating drug discovery for complex neurodegenerative diseases by leveraging extensive human genomic data and advanced computational biology. Their proprietary CONVERGE® platform integrates multi-omic patient data with machine learning to identify and validate therapeutic targets directly from human brain tissue, improving the likelihood of clinical success. The company focuses on diseases such as ALS and Parkinson’s, advancing programs from discovery through clinical development while collaborating with partners like Eli Lilly.
Compare with Alternatives
| Feature | Verge Genomics | Spate | TRM Labs | Tredence |
|---|---|---|---|---|
| Rating | 0.0 | 0.0 | 0.0 | 0.0 |
| Pricing | Paid | Paid | Paid | Paid |
| Starting From | — | — | — | — |
| API | — | — | — | — |
| Free Tier | — | — | — | — |
| Mobile App | — | — | — | — |
Who is it for
Target Discovery for Neurodegeneration
Identifying novel gene targets and pathways involved in diseases such as ALS and Parkinson’s directly from patient data.
Drug Candidate Development
Designing and optimizing therapeutic compounds based on validated targets to restore healthy gene network function.
Clinical Biomarker Identification
Linking gene expression and patient clinical data to find biomarkers that track disease progression and treatment response.
Accelerating Translational Research
Using human-centric data and machine learning to improve prediction of clinical outcomes and reduce drug development failures.